Harvard Business Review

JULY 23, 2015

For years, there has been a push within the pharmaceutical industry to move “beyond the pill” — in other words, to build and deploy complementary services and solutions to diversify revenue sources. However talented they might be, these individuals often lack experience building non-pharma service businesses.

Pharmaceuticals 8

Pharmaceuticals Health Care Industry Committee 8

Harvard Business Review

JUNE 22, 2016

Different industries and different business models have always maintained different percentages of these asset types. Digital transformation requires that companies reallocate their asset portfolio to support new, digitally enabled business models. The first step is to pinpoint your starting place.

Intangible Assets 10

Intangible Assets Business Model How To Intellectual Capital 10

Harvard Business Review

OCTOBER 23, 2014

The new business model has yet to solidify, and the leaders have yet to emerge. That’s why pharmaceutical, biotechnology, and medical device companies need to define their relevance in this new health care ecosystem, and soon. They are collaborating with (sometimes highly unlikely) partners. They’re also sharing risk.

Health Care 8

Health Care Pharmaceuticals Information Technology Supply Chain 8

Marshall Goldsmith

FEBRUARY 8, 2018

Lead author of Business Model Generation and Value Proposition Design , which sold over one million copies in 37 languages. Former HR director with Pepsi Central Eastern Europe, and gained HR expertise at PLIVA Pharmaceutical Company (now part of Teva Group). Alex Osterwalder – Co-founder Strategyzer. While at Arthur J.

Executive Coaching 70

Executive Coaching CEO Magazine Banking 70

Harvard Business Review

AUGUST 17, 2012

A more plausible explanation for Cipla's success, we believe, is that it matches its business model to the markets it want to grow in, rather than attempting to force a developed market business model on markets where it does not fit. and other traditionally developed markets. Cipla is not a stranger to M&A either.

Company 11

Company Pharmaceuticals Business Model Fixed Costs 11

Harvard Business Review

DECEMBER 20, 2011

Apple use life-cycle management to explore a new way to drive the business and business model forward. Throughout its history, Pfizer's biggest product and the biggest-selling branded drug in pharmaceutical industry history, has delivered some confounding strategic lessons. Both Pfizer and. Lipitor's Long Good-bye.

Disintermediation 15

Disintermediation Industry Pharmaceuticals Price 15

Harvard Business Review

AUGUST 14, 2018

ill-fated attempts to impose global business models unsuited to the Chinese market. failure to manage relations effectively with local business partners. As a culture market, China favors native firms, as they are often better at understanding users and the business environment. market on China.

Competitive Advantage 11

Competitive Advantage Business Model Technology Marketing 11

Harvard Business Review

MAY 1, 2014

I learned this while leading a turnaround of NPS Pharmaceuticals , a biotechnology company that now specializes in creating treatments for rare diseases. Accordingly, I transformed the business model ? from that of a fully integrated pharmaceutical company into a company that retained key technical expertise (e.g.,

Company 9

Company Pharmaceuticals Biotechnology Short-term 9

Harvard Business Review

JUNE 14, 2017

Their business models are at serious risk of failure in the next three to five years. Some firms have managed it, in healthcare and in other arenas — think of QuintilesIMS as a source of pharmaceutical sales data, Nielsen as the authority on TV viewer habits, and the U.S. Census for information about U.S. demographics.

Health Care 9

Health Care Levitt Competitive Advantage Pharmaceuticals 9

Harvard Business Review

NOVEMBER 8, 2017

The rising flood of hardware, pharmaceuticals, and technical expertise from American manufacturers and hospital companies, which is connected to the needs of a growing number of hospitals, is also pushing many systems closer to the U.S. Over the same period, pharmaceutical exports have doubled. Insight Center. Transforming Health Care.

Health Care 8

Health Care Tourism Pharmaceuticals Cost 8

Harvard Business Review

OCTOBER 29, 2012

The nay-sayers, on the other hand, can cite the passionately defended view of the pharmaceutical industry that the cost of discovering innovative disease-curing molecules has been rising crazily — the basis for perennial campaigns for stronger intellectual property rights to safeguard pharma investments.

Cost 8

Cost Innovation Wireless Disruptive Innovation 8

Harvard Business Review

JULY 4, 2017

The third playbook for an Apple vehicle is to create new categories , via breakthrough product innovation and breakthrough business model innovation. What parent who could afford it wouldn’t pay a premium for a car like this? And if you can put a living room on wheels, what else could you put on wheels? Or a kitchen?

Transportation 9

Transportation Sports Pharmaceuticals Health Care 9

Harvard Business Review

OCTOBER 26, 2017

Firms in the cluster design, manufacture, and assemble packaging machinery for a wide range of products, such as baked goods, confectionery, beverages, tea, tobacco, pharmaceuticals, and chemicals. They are known for demonstrating a special sensitivity to the market needs of the specialized manufacturers who use their services.

Education 8

Education Pharmaceuticals Innovation Industry 8

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

APRIL 19, 2016

Imagine the changes afoot in the pharmaceutical, medical device, automotive, and consumer electronics industries. It could upend supply chains, business models, customer relationships, and even entrepreneurship itself. 3D printing is poised to redefine global manufacturing and distribution.

Supply Chain 8

Supply Chain Execution Analysis Technology 8

Harvard Business Review

MAY 17, 2012

The founders came up with the idea for Embrace's frugal business model while they were all attending Stanford University's Entrepreneurial Design for Extreme Affordability program. Entrepreneurs often fall in love with their original product idea or business model and fail to listen to customers,'' Chen explains. ''We,

Incubator 11

Incubator Business Model Entrepreneur Cost 11

Harvard Business Review

NOVEMBER 12, 2018

In a recent Goldman Sachs research report about the promise of gene therapies, analysts asked a question that gets to the heart of a growing dilemma for the healthcare sector: “Is curing patients a sustainable business model?” New business models. Something has got to give.

Business Model 10

Business Model Insurance Cost Bond 10

Harvard Business Review

SEPTEMBER 19, 2013

The business models are unusual. They range from Ashoka , which deploys 3,000 citizen changemakers in 70 countries, to the global pharmaceutical giants that annually give away billions of dollars in medicine to low-income citizens. A new economy has emerged at the borderlands where traditional sectors overlap.

Pharmaceuticals 12

Pharmaceuticals Marketing Politics Bottom-up 12

Harvard Business Review

JANUARY 27, 2016

And use a business model with structural cost advantages (relative to existing solutions). The reason these characteristics of disruption are important are that when all three are present, it’s difficult for an existing business to respond to competition. Is 23andMe potentially disruptive to pharmaceutical companies?

Disruptive Innovation 8

Disruptive Innovation Innovation Short-term Long-term 8

Harvard Business Review

FEBRUARY 17, 2011

Nadathur's portfolio includes firms operating in drug discovery research, companion diagnostics, pharmaceutical analytics, reimbursement claims processing, patient relationship management, and specialty healthcare delivery for running clinical trials — and they all work together.

Marketing 15

Marketing Venture Capitalist Biotechnology IPO 15

Harvard Business Review

APRIL 22, 2015

Scale drove consolidation and globalization of industries throughout the mid-twentieth century and it still does today, such as in steel, airlines, pharmaceuticals, and telecommunications. There’s even a new name for vertical integration coming out of Silicon Valley: t he “Full Stack” business model.).

Six Sigma 8

Six Sigma Company Lean Production Taylorism 8

Harvard Business Review

OCTOBER 22, 2013

The business game is changing due to convergence — a process by which the boundaries across industries, businesses, markets, geographies, and/or customer experiences become blurred, resulting in new business opportunities for serving customer needs and improving customer value.

Skills 8

Skills Power Six Sigma Disruptive Innovation 8

Harvard Business Review

OCTOBER 26, 2011

It's easy to see why VCs have soured on the sector: the traditional VC model is based on high-risk, capital-efficient business models with the potential for huge exit valuations. Even if most of their investments fail, a few spectacular successes can "make the fund" for a VC.

Energy 11

Energy Finance IPO Biotechnology 11

Harvard Business Review

OCTOBER 24, 2017

In industries being disrupted by new entrants with distinct business models, incumbents often have an important advantage: entrenched regulatory and legal barriers. Jurgen Ziewe/Getty Images. These have forced AirBnB, Tesla, and Uber to make costly concessions to their operating practices or to exit certain markets altogether.

Licensing 9

Licensing Proposal Retail Long-term 9

Harvard Business Review

NOVEMBER 1, 2017

While the in-person DPPs were largely successful in reducing disease risk and incidence, Duffy and James recognized that there was substantial opportunity to better scale the DPP and make it more accessible and personalized by using technology.

Health Care 12

Health Care Participative Wireless Pharmaceuticals 12

Harvard Business Review

APRIL 22, 2013

Most of us think of biotech as the province of multinational pharmaceutical corporations and well-funded ventures, but the founders of BioCurious believe (as they say in their mission statement) "that innovations in biology should be accessible, affordable, and open to everyone."

Mission Statement 9

Mission Statement Class Learning-by-Doing Pharmaceuticals 9

Harvard Business Review

AUGUST 17, 2015

It could be an ideal location for healthcare organizations, but also for those in applied sciences, biotechnology, and pharmaceuticals. And secondly, the business model for Cuban biotechnology has been laughably bad. pharmaceutical company could be a great asset in the future. We know two things about biotech in Cuba.

Biotechnology 8

Biotechnology Tourism Human Capital Pharmaceuticals 8

Harvard Business Review

SEPTEMBER 10, 2013

Indeed, there are people like Hamdi Ulukaya (the Turkish founder of Chobani Greek Yogurt) or the founders of a variety of biotech and pharmaceutical firms who have achieved this through focusing on the purpose of healthier ways for us to eat and live. Fun is a good business model -- and it does not need to be a billion-dollar enterprise.

Fashion 8

Fashion Real Estate Retail Efficiency 8

Harvard Business Review

SEPTEMBER 20, 2013

Or a healthcare data offering evaluating physicians’ perceptions on a new drug may be useful not only to brand managers at pharmaceutical companies, but also to portfolio managers at asset management firms seeking to find promising investment opportunities.

Execution 8

Execution Metrics Content Christensen 8

Harvard Business Review

DECEMBER 5, 2016

Japanese pharmaceutical Eisai used them to improve care for Alzheimer’s patients. Their expectation was to spend about a day a week for the next six months on the identification, design, and testing of a business model innovation. in less than five years. Of course, more usage is good news.

Library 8

Library Strategy Reference Bottom-up 8

Harvard Business Review

FEBRUARY 4, 2013

Perhaps surprisingly, two leading examples come from pharmaceutical companies. We're moving towards innovation in technology, pricing, business models and partnerships," explains head of corporate responsibility management, Dorje Mundle, of the company's base-of-the-pyramid operations.

EPS 8

EPS Innovation CEO Pharmaceuticals 8

Harvard Business Review

SEPTEMBER 5, 2016

Cigna is the first insurance company to get pharmaceutical companies to agree to value pricing based on results for certain cholesterol-lowering drugs. recently announced that its members are committing to transform 75% of their contracts into pay-for-performance models by 2020. ” Health care.

Incentives 8

Incentives Health Care Education Insurance 8

Harvard Business Review

JUNE 3, 2016

It includes changes in how an organization interacts with its customers, citizens, or patients; in operational processes; in business models; in supply chain relationships; and in how employees use information to generate insight. Consequently, it is useful to think about investments in digital as essentially investments in change.

Tools 8

Tools Supply Chain CRM Technology 8

Harvard Business Review

OCTOBER 28, 2013

Ten years into her career there, in the mid-1990s, she realized that the agency’s business model was lacking a digital strategy. “I The department’s admin sent out the invite and downloaded the slides from the pharmaceutical company’s intranet site. Caroline Johanssen* was annoyed.

How To 12

How To Case Study Politics Reputation 12

Harvard Business Review

SEPTEMBER 7, 2015

Each team’s task was both to decide on pricing, investment, M&A and integration priorities and to experiment with new business models while anticipating and reacting to the actions of competitors and regulators. As an example, a large utility company created a number of different teams role playing competitors and regulators.

Seminar 8

Seminar Learning Curve Strategy Comparison 8

Strategy Driven

JANUARY 24, 2011

Closing the Execution Gap : How Great Leaders and Their Companies Get Results by Richard Lepsinger If an organization can’t execute its plans and initiatives, nothing else matters: not the most solid, well thought-out strategy, not the most innovative business model, not even technological breakthroughs that could transform an industry.

Execution 67

Execution Company 360-Degree Feedback Cooper 67

Harvard Business Review

MARCH 8, 2011

We don't understand the business models that will support real public private partnerships in the deployment and sustainability of mHealth systems. mHealth business models have emerged where there is one buyer for a solution to a specific problem. One is figuring out the proper mix of public and private involvement.

Wireless 15

Wireless Health Care Pharmaceuticals Business Model 15